Oncogenes are commonly amplified on particles of extrachromosomal DNA (ecDNA) in cancer
1 , 2 , but our understanding of the structure of ecDNA and its effect on gene regulation is …

Cancer immunoresistance and immune escape 1 , 2 , 3 may play important roles in tumor
progression and pose obstacles for immunotherapy. Expression of the immunosuppressive …

Background The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to …

Background There is much discussion in the cancer drug development community about
how to incorporate molecular tools into early-stage clinical trials to assess target modulation, …

Comprehensive knowledge of the genomic alterations that underlie cancer is a critical
foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to analyze …

Systematic efforts are underway to decipher the genetic changes associated with tumor
initiation and progression 1 , 2 . However, widespread clinical application of this information is …

In current clinical practice, histology-based grading of diffuse infiltrative gliomas is the best
predictor of patient survival time. Yet histology provides little insight into the underlying …

Purpose: We previously reported that autologous dendritic cells pulsed with acid-eluted tumor
peptides can stimulate T cell–mediated antitumor immune responses against brain tumors …

Human cells have twenty-three pairs of chromosomes. In cancer, however, genes can be
amplified in chromosomes or in circular extrachromosomal DNA (ecDNA), although the …

The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in ∼20% of non-small
cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-…